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Abstract. The goal of this study was to determine the presence of the genes implicated in resistance to agents used for
chemotherapy of infectious diseases caused by Pseudomonas aeruginosa. Twenty seven P. aeruginosa isolates from the Clinical
Hospital for Infectious Diseases in Cluj-Napoca, Romania, were analyzed. The bacteria were isolated over two years period, in 2008
and 2009 and serotyped at the Clinical Hospital of Infectious Disease, Cluj-Napoca. The isolates were recovered from patients with
multiple types of infections, mostly respiratory tract, urinary tract and postoperative wound infections. In order to identify the genes
implicated in antimicrobial resistance mechanisms, we used a direct PCR technique. DNA extraction was skipped and the bacterial
cell wall denaturated in the first step of the reaction. We did not identify the presence of blaVIM or blaIMP family genes at any of the
tested isolates of P. aeruginosa. We determined instead the PstS gene and from the ESBL group, we detected the presence of OXA
type genes, namely OXA-50 and OXA-2. The presence of blaOXA-50 is important in order to identify and track the spread of
multidrug-resistant P. aeruginosa clones since that blaOXA-50may be another potential clonality marker. This study is the first report
of presence of PstS and blaOXA type genes in P. aeruginosa isolates, in Romania.
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INTRODUCTION
Nosocomial infections are an important source of
morbidity and mortality in many hospitals affecting
millions of patients each year [25]. P. aeruginosa is
one of the most important nosocomial pathogens, being
responsible for various types of infections with more
and more limited therapeutic options [4]. Infection due
to P. aeruginosa c o n t i n u e s  t o  b e  a  m a j o r  c a u s e  o f
mortality among critically ill and immuno-
compromised patients despite the development of
newer and more powerful antibiotics. P. aeruginosa is
characterized by inherent resistances to a wide variety
of antimicrobials. Its intrinsic resistance to many
antimicrobial agents and its ability to develop
multidrug resistance imposes a serious therapeutic
problem [5]. Multi-drug–resistant (MDR) strains of P.
aeruginosa, defined as resistant to at least three of the
following antibiotics: ceftazidime, imipenem,
gentamicin or ciprofloxacin, are often isolated from
patients exposed to prolonged intensive care-type
therapies [30]. Its resistance to anti-pseudomonal b-
lactams, advanced generation of cephalosporins,
monobactams and carbapenems is also an increasing
clinical problem. Carbapenems, mainly imipenem and
meropenem, are potent agents for the treatment of
infections due to multidrug-resistant (MDR) P.
aeruginosa. The immunoevasive nature of P.
aeruginosa as well as its acquisition of multi-drug
resistance makes elimination of this organism a
particular challenge. Yet antibiotic resistance itself
does not confer enhanced virulence [29], and therefore
the ability to discriminate between virulent versus non-
virulent phenotypes among multi-drug resistant isolates
would be a major step in predicting the particular threat
of a colonizing strain of P. aeruginosa.
Historically, the analysis of nosocomial pathogens
has relied on a comparison of phenotypic
characteristics such as biotypes, serotypes and
antimicrobial susceptibility profiles [26]. This
approach has begun to change over the past 2 decades,
with the development and implementation of new
technologies based on DNA or molecular analysis.
Studies of microbial pathogenicity at the molecular
level have made substantial contributions to our
understanding of the epidemiology, clinical
manifestations, diagnosis, treatment, and
immunoprophylaxis of infectious diseases. One of the
most exciting and profound technical advances in the
past years has been the development of nucleic acid
amplification techniques and their application to the
study of microbial pathogenesis and the diagnosis of
infectious diseases. Comparing with traditional
methods, molecular analysis has a higher accuracy, and
results are obtained much faster and much cheaper.
In this study, our goal was to identify the presence
of bacterial genes involved in multiple resistances to
antimicrobials at P. aeruginosa using the PCR method.
MATERIALS AND METHODS
Clinical isolates. We examined 27 clinical isolates
of P. aeruginosa from the Clinical Hospital for
Infectious Diseases in Cluj-Napoca, Romania, a
medical center treating patients from all over the
western part of Romania. The bacterial isolates were
collected between September 2008 and October 2009
from patients with multiple types of infections, mostly
respiratory tract, urinary tract, postoperative wound
infections and sporadic infections. The isolates were
identified with Vitek 2 Compact for Gram-Negative
Identification, card 2GN (bioMerieux-Vitek, Inc.,
Hazelwood, Mo.).
Antimicrobial susceptibility testing.
Antimicrobial susceptibility tests were performed by
Kirby-Bauer or disk diffusion method and minimum
inhibitory concentration (MIC) method with Vitek 2
Compact system for Gram-Negative bacteria, card
AST-NO22, according to the recommendations of the
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The MICs of potent antibiotics for P. aeruginosa,
including, quinolones (ciprofloxacin, pefloxacin),
aminoglycosides (gentamicin, amikacin, tobramycin),
betalactams: carboxypenicillin (ticarcillin),
ureidopenicillin (piperacillin), carboxipenicillin and
ureidopenicillin with betalactamases inhibitors
(piperacillin/tazobactam, ticarcillin/clavulanic acid),
third-generation cephalosporin (ceftazidime), fourth
generation cephalosporin (cefepime, cefpirome),
monobactams (aztreonam) and polymyxins B (colisin)
were determined. P. aeruginosa ATCC 27853, and
Escherichia coli ATCC 25922 were used as reference
strains in susceptibility testing.
Preparation of samples and DNA amplification.
We used a direct PCR technique, DNA extraction was
skipped and the bacterial cell wall denaturated in the
first step of the reaction. One or two bacterial colonies
from a plate that was incubated overnight were
suspended in 100 ml of sterile water and then diluted to
a concentration of approximately 10
6 CFU/ml. 3 µl of
t h i s  s u s p e n s i o n  w a s  u s e d  a s  t h e  t e m p l a t e  f o r
amplification by PCR. Using this technique we can
skip the expensive DNA extraction and the self
contamination of workers is minimized [7]
PCR protocol
A typical 25-µl PCR mixture contained 2.5 µl
10xPCR reaction buffer, 25 pmol of each primer, 200
µM concentrations of each dNTP, 2 µl MgCl2 25 mM
(2 mM final concentration) 0.75 U of Taq polymerase,
and 3 µl bacterial suspension. PCR was performed in a
Thermocycler, (Gradient Palm-Cycler™ ,Corbett Life
Science). The parameters for amplification were as
follows: initial denaturation at 94
oC for 4 min, 30
c y c l e s  o f :  1  m i n  e a c h  a t  9 4
o C, 1 min. at 55-60
oC
(depending on the primer), 1 min. at 72
oC and a final
extension step at 72
oC for 10 min. Amplicons have
b e e n  s e p a r a t e d  o n  1 . 5  %  a g a r o s e  g e l ,  s t a i n e d  w i t h
ethidium bromide. The optimisation of PCR was made
after McPherson and Møller, (2001) [12] and Roux,
(2003) [24]. The primers (Table 1) were designed with
“Pick Primers” programe (http://biotools.umassmed.
edu accessed in September 2010) according to the
sequences found at NCBI data base . A primer pair
targeting the consensus region of the bacterial 16S
rRNA gene was used as a PCR internal-control target
Table 1 Primers used for PCR amplification
Target gene Function Sequence (5’→3’) Amplicon size
(pb)
Accesion no.
IMP-7 b-lactamase
AAGGCAGTATCTCCTCTCATTTTC/
ACTCTATGTTCAGGTAGCCAAACC
243 EF606914
IMP-10 b-lactamase
AATGCTGAGGCTTACCTAATTGAC/
CCAAGCTTCTATATTTGCGTCAC
388 DQ288156
IMP-13 b-lactamase
AGACGCCTATCTAATTGACACTCC/
CCACTAGGTTATCTTGAGTGTGACC 311 AM931299
IMP-25 b-lactamase
GCAGTATTTCCTCACATTTCCATAG/
TCACCCAAATTACCTAGACCGTAG
295 EU352796
VIM-7 b-lactamase
TATCCGACAGTAGATGACATACCG/
CTAGAGGAGAGCGCTTTTAGAGAG
386 NC009739
PstS multidrug
resistance
GGCTTTCGAGCAGAAGTACG/
ATGTAGCCGTCCTTGACCAC
606 EF601159
blaOXA-50 ESBL GAAAGGCACCTTCGTCCTCTAC/
CAGAAAGTGGGTCTGTTCCATC 400 AM117128
blaOXA-2 ESBL ATACACTTTTTGCACTTGATGCAG/
TGAAAAGATCATCCATTCTGTTTG 510 AJ620678
ARNr 16S consensus
region
AGAGTTTGATCCTGGCTCAG/
ACGGCTACCTTGTTACGACTT 1499 HM045838
RESULTS
Phenotypic traits. All tested strains were sensitive
to colistin, three strain were susceptible only to
imipenem and meropenem, one was susceptible only to
piperacillin-tazobactam and seven of them were
sensitive to aztreonam and resistant to all others
antibiotics. Two isolates were susceptible to all the
antibiotic that we tested.
PCR failed to detect VIM-7 and IMP family tests
whereas controls with blaIMP and blaVIM genes yielded
PCR products of the expected sizes. Amplicons of the
expected sizes were obtained for PstS, blaOXA 50 and
blaOXA-2 genes at the isolates that were resistant to
antimicrobials (Fig. 1, 2 and 3). At the sensitive
isolates amplicons were not obtained.
The results of the amplification using the primer
pair targeting the consensus region of the bacterial 16S
rRNA gene are presented in fig. 4.
DISCUSSION
P. aeruginosa is one of the most important nosocomial
pathogens, being responsible for various types of
infections with more and more limited therapeutic
options. One of the most alarming characteristic of P.
aeruginosa is its low antibiotic susceptibility. This
situation is due in large part to the rapid accumulation
of antimicrobial resistance mechanisms. The four main
mechanisms by witch microorganisms exhibit
resistance to antimicrobials are: drug inactivation
through the production of b-lactamases, alteration of
target site (e.g. alteration of PBP-the target site of
penicillins), alteration of metabolic pathway and
reduced drug accumulation by decreasing drug
permeability and/or increasing active efflux (pumping
out) of the drug across the cell surface.
Development of multidrug resistance by P.
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events including acquisition of different mutations
and/or horizontal transfer of antibiotic resistance genes.
In this study we used PCR method in order to
identify the genes implicated in antimicrobial
resistance mechanisms (MDR included) in P.
aeruginosa isolates collected in an important medical
center from the western part of our country.
Since the first report of acquired metallo-b-lactamase
(MBL) in Japan in 1994 [19], genes encoding IMP-
and VIM type enzymes have spread rapidly among
Pseudomonas spp. [13, 24, 29]. Acquired metallo-b-
lactamases (MBLs) are mostly encoded by integron-
borne genes and confer resistance against all b-lactams
except for the monobactams. VIM-type MBLs were
reported from several European countries and also
from countries outside Europe such as Korea and the
United States [10, 18, 21, 27]. The prevalence of MbL-
producing gram-negative bacilli has increased in some
hospitals, particularly among clinical isolates of P.
aeruginosa [23]. Since MBL production may confer
phenotypic resistance to virtually all clinically
available b-lactams, the continued spread of MBL is a
major clinical concern [28].
Figure 1. Agarose gel electrophoresis of PCR products after amplification of PstS gene. Lanes: 1 – molecular weight marker (O’Range Ruler 100
DNA Ladder, SM1143-Fermentas); 2-16– different strains of P. aeruginosa (PstS gene products).
Figure 2. Agarose gel electrophoresis of PCR products after amplification of blaOXA-50gene. Lanes: 1–molecular weight marker (O’Range Ruler 100
DNA Ladder, SM1143-Fermentas); 2-19–different strains of P. aeruginosa (blaOXA-50gene products).
Figure 3. Agarose gel electrophoresis of PCR products after amplification of blaOXA-2 gene. Lanes: 1 and 17-molecular weight marker (O’Range
Ruler 100 DNA Ladder, SM1143-Fermentas); 2-16–different strains of P. aeruginosa (blaOXA-2 gene products).
Figure 4. Agarose gel electrophoresis of PCR products after amplification of the consensus region of the bacterial 16S rRNA. Lanes: 20-molecular
weight marker (O’Range Ruler 100 DNA Ladder, SM1143-Fermentas); 1-5, 7-16 and 18–different strains of P. aeruginosa; 6, 17, 19-
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With the recent detection of IMP and VIM-
producing strains in several Eastern-European
countries [21, 25], the appearance of MBL-producing
clinical isolates of P. aeruginosa can be anticipated in
Romania. Our results suggest the lack of these blaVIM
and blaIMP genes at tested isolates. Further studies are
n e c e s s a r y  t o  c o n c l u d e  t h a t  t h i s  g e n e s  f a m i l y  i s  n o t
present in the P. aeruginosa isolates circulating in this
area of the country.
Extended-spectrum b-lactamases (ESBLs) that
confer resistance to oxyimino-b-lactams are frequently
plasmid encoded. PER (Pseudomonas extended
resistant) b-lactamases are one of the rarer ESBL
families; however, their prevalence may be increasing
[4]. Since 1995, PER producing organisms have been
disseminating in Italy [20, 22] and, more recently, in
Belgium [16], France [3], Spain [14], Romania [17],
Hungary and Serbia [11], Korea [8], Japan [29], and
China [6].
F r o m  t h e  E S B L  g r o u p ,  w e  d e t e c t e d  o n l y  t h e
presence of OXA type b-lactamases, namely OXA-50
and OXA-2 at the tested isolates. These genes were
found mainly in P. aeruginosa isolates from Turkey [1,
9] and France [3]. This aspect is important in order to
identify and track the spread of multidrug-resistant P.
aeruginosa clones since that blaOXA-50 may be another
potential clonality marker for P. aeruginosa [4].
PstS is another gene that we identified in almost all
tested isolates. PstS proteins are the cell-bound
phosphate-binding elements of the ubiquitous bacterial
ABC phosphate uptake mechanisms. Primary and
tertiary structures, characteristic of pstS proteins, are
conserved in proteins, which are expressed in secretory
operons and induced by phosphate deprivation, in
Pseudomonas species [ 2 ,  1 5 ] .  T h e  p r e s e n c e  o f  t h i s
periplasmic phosphate binding protein (PstS) confers a
highly virulent phenotype of MDR isolates of P.
aeruginosa [31].
Our study revealed that PstS, OXA-50 and OXA-2
genes are implicated in antimicrobial resistance
mechanisms in MDR tested isolates of P. aeruginosa.
Further studies are necessary to conclude if other genes
contribute to the antimicrobial resistance in P.
aeruginosa strains, in our country.
This study is the first report of presence of PstS and
b l a O X A  t y p e  g e n e s  i n P. aeruginosa isolates, in
Romania. A regular screening and monitoring system
should be set up to prevent the spread of the resistance
determinants in the country.
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